5.72
+0.36(+6.72%)
Currency In USD
Address
2625 Townsgate Road
Westlake Village, CA 91361
United States of America
Phone
858 483 0024
Website
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
January 26, 2023
| Name | Title | Pay | Year Born |
| Mr. Thomas Zindrick J.D. | Chairman, Chief Executive Officer & President | 598,048 | 1960 |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development | 242,615 | 1971 |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer | 363,048 | 1957 |
| Mr. Sean Ryder J.D. | General Counsel & Corporate Secretary | 380,000 | 1969 |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer | 0 | 1945 |
| Mr. Matthew Pulisic M.B.A. | Chief Financial Officer and Principal Financial & Accounting Officer | 0 | 1984 |
| Mr. Ralph Smalling B.Sc. | Vice President & Head of Regulatory Affairs | 0 | 1955 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.